BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18841055)

  • 1. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.
    Mrózek K; Marcucci G; Paschka P; Bloomfield CD
    Curr Opin Oncol; 2008 Nov; 20(6):711-8. PubMed ID: 18841055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
    Marcucci G; Caligiuri MA; Bloomfield CD
    Cancer Invest; 2000; 18(8):768-80. PubMed ID: 11107447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
    Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
    Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Core binding factor acute myeloid leukemia.
    Paschka P
    Semin Oncol; 2008 Aug; 35(4):410-7. PubMed ID: 18692691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
    Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
    Mrózek K; Bloomfield CD
    J Natl Cancer Inst Monogr; 2008; (39):52-7. PubMed ID: 18648004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia.
    Shurtleff SA; Meyers S; Hiebert SW; Raimondi SC; Head DR; Willman CL; Wolman S; Slovak ML; Carroll AJ; Behm F
    Blood; 1995 Jun; 85(12):3695-703. PubMed ID: 7780153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Mrózek K; Prior TW; Edwards C; Marcucci G; Carroll AJ; Snyder PJ; Koduru PR; Theil KS; Pettenati MJ; Archer KJ; Caligiuri MA; Vardiman JW; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2001 May; 19(9):2482-92. PubMed ID: 11331327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia].
    Ishikawa Y
    Rinsho Ketsueki; 2018; 59(10):1997-2006. PubMed ID: 30305502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.
    Eisfeld AK; Kohlschmidt J; Schwind S; Nicolet D; Blachly JS; Orwick S; Shah C; Bainazar M; Kroll KW; Walker CJ; Carroll AJ; Powell BL; Stone RM; Kolitz JE; Baer MR; de la Chapelle A; Mrózek K; Byrd JC; Bloomfield CD
    Leukemia; 2017 Jun; 31(6):1278-1285. PubMed ID: 27843138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core binding factor acute myeloid leukemia (CBF-AML) in México: a single institution experience.
    Ruiz-Delgado GJ; Macías-Gallardo J; Lutz-Presno J; Garcés-Eisele J; Hernández-Arizpe A; Montes-Montiel M; Ruiz-Argüelles GJ
    Rev Invest Clin; 2011; 63(1):25-30. PubMed ID: 21574542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
    Marcucci G; Caligiuri MA; Bloomfield CD
    Eur J Haematol; 2003 Sep; 71(3):143-54. PubMed ID: 12930314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.
    Larmonie NSD; Arentsen-Peters TCJM; Obulkasim A; Valerio D; Sonneveld E; Danen-van Oorschot AA; de Haas V; Reinhardt D; Zimmermann M; Trka J; Baruchel A; Pieters R; van den Heuvel-Eibrink MM; Zwaan CM; Fornerod M
    Oncogene; 2018 Jan; 37(1):107-115. PubMed ID: 28892045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive profile of cytogenetics in 2308 Chinese children and adults with de novo acute myeloid leukemia.
    Li X; Li X; Xie W; Hu Y; Li J; Du W; Liu W; Li H; Chen X; Zhang L; Wang J; Huang S
    Blood Cells Mol Dis; 2012 Aug; 49(2):107-13. PubMed ID: 22683308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
    Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
    Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia.
    Mrózek K; Bloomfield CD
    Hematology Am Soc Hematol Educ Program; 2006; ():169-77. PubMed ID: 17124057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of c-KIT and CEBPA mutations in 33 patients with corebinding factor (Non-M3) acute myeloid leukemia.
    Mao X; Yin R; Liu L; Zhou Y; Yang C; Fang C; Jiang H; Guo Q; Tian X
    Pediatr Neonatol; 2023 Jul; 64(4):435-441. PubMed ID: 36809862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.